SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	12.27	7.08	4.27
Research & Development	29.18	19.98	9.96
Total Operating Expenses	41.45	27.06	14.23
Operating Income	-41.45	-27.06	-14.23
Interest Income	3.11	1.32	0.91
Other Non-Operating Income (Expense)	-1.53	-3.42	-
Total Non-Operating Income (Expense)	1.58	-2.1	0.91
Pretax Income	-39.87	-29.16	-13.32
Net Income	-39.87	-29.16	-13.32
Net Income to Common	-39.87	-29.16	-13.32
Shares Outstanding (Basic)	2	2	2
Shares Outstanding (Diluted)	2	2	2
Shares Change (YoY)	23.98%	2.89%	-
EPS (Basic)	-17.98	-16.31	-7.66
EPS (Diluted)	-17.98	-16.31	-7.66
Shares Outstanding	2.2	2.2	1.75
Free Cash Flow	-33.49	-24.02	-12.49
Free Cash Flow Per Share	-15.11	-13.43	-7.19
EBITDA	-40.84	-26.79	-14.11
EBIT	-41.45	-27.06	-14.23

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q